CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 16 enrolled
Drug / intervention
Seminal plasma pharmacokineticsother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01045265
NCT01045265N/ACompleted

Study to Determine the Concentrations of Raltegravir in Semen, the Seminal to Plasma Ratio of Raltegravir and the Variability in Seminal to Plasma Ratios Over the Raltegravir Dosing Period.

Canadian Immunodeficiency Research Collaborative·observational·Posted Jan 11, 2010·Updated Aug 13, 2014

In Brief

An observational study evaluating Seminal plasma pharmacokinetics for HIV. Completed, enrolled 16 participants across 2 sites.

Detailed Summary

The objective of this study is to determine if concentrations of raltegravir in semen exceed the 50% and 95% inhibitory concentrations of HIV during the dose interval. The secondary objective is to determine the extend of raltegravir penetration into semen by obtaining semen to plasma ratios across the dosing interval, to determine the area under the concentration time curve of raltegravir in semen, and to determine the variability in the penetration of raltegravir into the seminal compartment over the dosing period.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHIV
CountriesCanada
Collaborators--

Timeline

N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 11, 2010
Enrollment StartDec 1, 2009
Primary CompletionSep 1, 2011
Study CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 16.5 years ago

Interventions

Seminal plasma pharmacokineticsother

Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.